Perceptive Advisors’s Grace Therapeutics GRCE Stock Holding History

Perceptive Advisors’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-37,081	Closed	-$4.36M	–	127
2019 Q4	$4.36M	Hold	37,081	–	–	0.09%	81
2019 Q3	$3.36M	Hold	37,081	–	–	0.09%	79
2019 Q2	$2.03M	Hold	37,081	–	–	0.05%	84
2019 Q1	$1.81M	Hold	37,081	–	–	0.05%	77
2018 Q4	$1.48M	Buy	+37,081	New	+$1.62M	0.06%	76
2018 Q3	–	Sell	-4,306	Closed	-$117K	–	137
2018 Q2	$117K	Buy	4,306 +419	+11%	+$16.1K	﹤0.01%	122
2018 Q1	$190K	Hold	3,887	–	–	0.01%	131
2017 Q4	$176K	Hold	3,887	–	–	0.01%	129
2017 Q3	$267K	Hold	3,887	–	–	0.01%	134
2017 Q2	$247K	Hold	3,887	–	–	0.01%	122
2017 Q1	$254K	Hold	3,887	–	–	0.01%	131
2016 Q4	$233K	Sell	3,887 -1,041	-21%	-$69.9K	0.02%	139
2016 Q3	$414K	Hold	4,928	–	–	0.03%	144
2016 Q2	$336K	Hold	4,928	–	–	0.02%	137
2016 Q1	$360K	Hold	4,928	–	–	0.03%	140
2015 Q4	$594K	Hold	4,928	–	–	0.04%	96
2015 Q3	$626K	Hold	4,928	–	–	0.05%	106
2015 Q2	$745K	Hold	4,928	–	–	0.04%	125
2015 Q1	$1.13M	Sell	4,928 -434	-8%	-$102K	0.09%	99
2014 Q4	$1.29M	Hold	5,362	–	–	0.11%	99
2014 Q3	$1.98M	Buy	5,362 +15	+0.3%	+$7.05K	0.2%	71
2014 Q2	$2.44M	Sell	5,347 -631	-11%	-$301K	0.24%	60
2014 Q1	$3.3M	Sell	5,978 -3,167	-35%	-$1.93M	0.35%	56
2013 Q4	$5.24M	Buy	9,145 +8,823	+2,740%	+$7.23M	0.63%	36
2013 Q3	$366K	Buy	+322	New	+$479K	0.03%	82

Other funds holding GRCE

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JLBC

J.L. Bainbridge & Co Sarasota, Florida $1.27B AUM 26.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Perceptive Advisors's GRCE Position: Q1 2020 in Review

Perceptive Advisors sold out of Grace Therapeutics (GRCE) in Q1 2020, closing a stake of 37,081 shares — an estimated $4.36M sold.

Perceptive Advisors first reported a position in GRCE in Q3 2013 and held it in 25 quarters. The position peaked at $5.24M in Q4 2013. 26 funds tracked by Wall St. Rank hold GRCE as of Q1 2020.

Perceptive Advisors reported no remaining Grace Therapeutics position as of Q1 2020 after selling out during the quarter.
Perceptive Advisors sold 37,081 Grace Therapeutics shares in Q1 2020, an estimated $4.36M.
Perceptive Advisors first reported a position in Grace Therapeutics in Q3 2013 and held it in 25 quarters.
Perceptive Advisors's Grace Therapeutics position peaked at $5.24M in Q4 2013.
26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2020.

Based on Perceptive Advisors's 13F filing for Q1 2020, filed 15 May 2020.